Quick Links

A Fireside Chat: The Australian Clinical Trial Advantage

Did you know? Of the 13 new drugs approved by the FDA… MORE

The Three Hottest Trends in Neuroscience Research: Part III

Neuroscience Trials Australia CEO Dr Tina Soulis has traversed the globe attending… MORE

The Three Hottest Trends in Neuroscience Research Part II

Neuroscience Trials Australia CEO Dr Tina Soulis has traversed the globe attending… MORE

New to Neuro

A Fireside Chat: The Australian Clinical Trial Advantage

Did you know? Of the 13 new drugs approved by the FDA in 2016, 7 had Phase III trials conducted in Australia.

Every year, the J.P. Morgan Healthcare Conference brings together the global biotech, biopharma and medtech community to discuss the latest innovations in the industry, announce breaking deals and explore the most promising investment opportunities. As a hotbed for emerging therapeutics and technologies, and the sector’s biggest movers and shakers, the J.P. Morgan Healthcare Conference provided the perfect platform to share the advantages of undertaking clinical trials in Australia.

To this end, Neuroscience Trials Australia with the sponsorship of the State Government of Victoria, hosted a fireside chat with guest panellists Dr Daniel Abrams (CEO, Cerebral Therapeutics), Dr RJ Tesi (Co-founder & CEO, InmuneBio), Dr CJ Barnum (Director, InmuneBio), Jessica Ballinger (COO, Lyndra Therapeutics) and Dr Kiran Reddy (President & CEO, Praxis Precision Medicines).

Discussing their experiences working in Australia, the panellists agreed that the easy of study submission, approval time, high-quality data, rigorous science and tax incentives made the country a very attractive option, especially for early phase studies. This was evidenced by the fact that all of our panellists returned to Australia following their first studies and planned to continue to work in Australia in their future development programs.

Another advantage that arose from discussions was the collaborative nature across the spectrum of Australian stakeholders, from clinicians to service providers. Notably, it was found that there was a strong culture of being open to sharing ideas in Australia, which contributed significantly to successful projects.

However, some panellists did note some particular challenges – specifically, Australia’s location. But this challenge was overcome by the 24-hour coverage of studies. Ultimately, there was consensus about the importance of selecting experienced vendors who are able and willing to work with clients closely and with trust. This element was integral to the success of studies and it was one that Australia’s clinical trials landscape possessed.

We would like to thank all attendees and look forward to hosting similar events at J.P. Morgan Healthcare Conference in the future!